Form 10-Q · Quarterly report
Leidos 10-Q, filed Nov 3, 2026
- Filed
- CIK
- 0001336920
- Accession no.
- 0001336920-26-000293
Summary
Leidos reported third-quarter fiscal 2026 revenues of $4.63 billion, up 3.6%, and net income attributable to common stockholders of $410 million, up 11.7%, while realigning into four reportable segments. The company closed the divestiture of its SES Business on October 5, 2026, retaining a 41.5% non-controlling stake in a joint venture with Altaris holding 58.5%.
Key points
- Leidos' third-quarter fiscal 2026 revenues were $4.630 billion, up 3.6% from $4.469 billion a year earlier.
- Net income attributable to Leidos common stockholders was $410 million, up 11.7%, while nine-month net income attributable fell 2.6% to $1.092 billion.
- Homeland segment revenues rose 32.1% to $1.024 billion in the quarter, including $142 million from the Entrust acquisition.
- The SES Business divestiture closed on October 5, 2026, with Leidos retaining a 41.5% non-controlling equity interest in the joint venture and Altaris holding 58.5%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion OVERVIEW Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 50,000 global employees, we pursue strategic growth across five pillars: defense tech; energy infrastructure; cyber; mission and digital solutions; and managed health services. Our customers include the U.S. Department of War (“DoW”), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs, and many other U.S. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.